| Date | Title | Description |
| 31.10.2025 | Oncoinvent appoints Dr. Ramzi Amri as new CFO | Oncoinvent appoints Dr. Ramzi Amri as new CFO
Fri, Oct 31, 2025 08:30 CET Report this content
Oncoinvent ASA (OSE: ONCIN) today announces the appointment of Dr. Ramzi Amri, M.D., Ph.D. as Chief Financial Officer (CFO), effective on or aroun... |
| 06.08.2025 | Swiss stocks decline as officials head to the U.S. to negotiate tariffs | This was CNBC’s live blog covering European markets.
Swiss stocks declined on Wednesday as the country’s President and economic minister were meeting U.S. government officials in an attempt to lower the 39% tariffs imposed by President Trum... |
| 18.06.2025 | Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate G... | Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufacturing
GLPG5101 demonstrated promising efficacy with ... |
| 18.06.2025 | Galapagos presenteerde nieuwe gegevens op ICML 2025 van Cohort 3 van de ATALANTA-1 studie bij patiënten met recidief/refractair indolent NHL, en toonde hoge complete respons- en MRD-negativiteitsperce... | Van de 34 patiënten die werden ingeschreven in Cohort 3 van de ATALANTA-1 fase 1/2-studie, ontvingen er 32 GLPG5101; 94% kreeg verse CAR T-cellen toegediend, en 93% werd behandeld binnen zeven dagen na productie GLPG5101 toonde veelbelovend... |
| 12.06.2025 | Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL | Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities
Of the 64 patients enrolled, 61 receive... |
| 12.06.2025 | Galapagos zal nieuwe ATALANTA-1 CAR-T data presenteren op EHA 2025, met lage toxiciteit en snelle, gedecentraliseerde toediening van vers, early-memory-verrijkt GLPG5101 bij R/R NHL | Gegevens uit de lopende ATALANTA-1 fase 1/2-studie bij een zwaar voorbehandelde patiëntengroep met recidief/refractair non-Hodgkinlymfoom (R/R NHL) tonen lage percentages van hooggradige toxiciteiten aan
Van de 64 ingeschreven patiënten wer... |
| 26.04.2025 | Granite Bio: A New Force in Immunology with $100 Million Backing | Granite Bio has burst onto the scene, armed with $100 million in funding. This clinical-stage immunology company is not just another player; it’s a potential game-changer. With a focus on autoimmune diseases, Granite Bio is targeting the ro... |
| 25.04.2025 | Granite Bio: Immunology Company Debuts With $100 Million In Funding | Granite Bio, a clinical-stage immunology company, announced it has emerged from stealth with $100 million in funding. This includes a $30 million Series A led by founding investors Versant Ventures and Novartis Venture Fund and a $70 millio... |
| 21.04.2025 | Galapagos Announces Executive Leadership Updates | Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the next 12 months and plans to... |
| 21.04.2025 | Galapagos kondigt wijzigingen aan in uitvoerend leiderschap | De heer Henry Gosebruch benoemd door de Raad van Bestuur van Galapagos als oprichtend CEO van het nieuw opgerichte SpinCo
Dr. Paul Stoffels, Voorzitter en CEO van Galapagos, is van plan in pensioen te gaan als CEO na benoeming van een opvol... |
| 15.04.2025 | Galapagos kondigt het vertrek van haar CFO en COO, Thad Huston, aan per 1 augustus 2025 | Mechelen, België; 15 april 2025, 07:30 CET; gereglementeerde informatie - voorwetenschap – Galapagos NV (Euronext & NASDAQ: GLPG), een wereldwijd biotechnologiebedrijf dat zich toelegt op het transformeren van patiëntresultaten door mid... |
| 15.04.2025 | Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025 | Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science a... |
| 27.03.2025 | Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders’ Meeting | Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders’ Meeting (AGM) to be held o... |
| 27.03.2025 | Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders’ Meeting | Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders’ Meeting (AGM) to be held o... |
| 27.03.2025 | Galapagos publiceert 2024 jaarverslag en kondigt jaarlijkse Gewone Algemene Vergadering aan | Mechelen, België; 27 maart 2025, 21:01 CET; gereglementeerde informatie - Galapagos NV (Euronext & NASDAQ: GLPG) publiceert vandaag haar jaarverslag over het boekjaar 2024 en kondigt haar jaarlijkse Gewone Algemene Vergadering (AV) aan ... |
| 17.02.2025 | Galapagos ontvangt transparantieverklaring en 13D-filing van Tang Capital | Mechelen, België; 17 februari 2025, 22:01 CET; gereglementeerde informatie - Galapagos NV (Euronext & NASDAQ: GLPG) heeft een kennisgeving van belangrijke deelneming en 13D filing ontvangen van Tang Capital.
Overeenkomstig de Belgische ... |
| 17.02.2025 | Galapagos receives transparency notification and 13D filing from Tang Capital | Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital.
Pursuant to Belgian transparency legislation1, Galapa... |
| 17.02.2025 | Galapagos receives transparency notification and 13D filing from Tang Capital | Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital. Pursuant to Belgian transparency legislation1, Galapa... |
| 12.02.2025 | Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update | Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein
Focusing on accelerating GLPG5101 progra... |
| 10.02.2025 | NecstGen Partners with Galapagos to Advance Decentralised CAR-T Cell Manufacturing in Europe | NecstGen Clean Cleanroom for CAR-T Production
NecstGen, a leading Contract Development and Manufacturing Organization (CDMO) dedicated to Cell and Gene Therapies, announces a collaboration with Galapagos NV LEIDEN, NETHERLANDS, February 10,... |
| 07.01.2025 | Galapagos presenteert op de 43ste jaarlijkse J.P. Morgan Healthcare Conference | Mechelen, België; 7 januari 2025; 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) heeft vandaag aangekondigd dat het bedrijf een presentatie zal geven op de 43ste jaarlijkse J.P. Morgan Healthcare Conference op woensdag 15 januari 20... |
| 07.01.2025 | Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in Sa... |
| 07.12.2024 | Galapagos kondigt bemoedigende nieuwe resultaten aan van de lopende fase 1/2-studie van de CD19 CAR T-celtherapie GLPG5101 bij patiënten met recidief/refractair non-Hodgkin lymfoom | De resultaten van de lopende fase 1/2 ATALANTA-1 studie in een zwaar voorbehandelde R/R NHL patiëntenpopulatie tonen hoge anti-tumoractiviteit en een bemoedigend veiligheidsprofiel in alle onderzochte NHL-subtypes. 96% van de patiënten kreg... |
| 07.12.2024 | Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma | Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied.96% of patients received an infusion of fr... |
| 07.12.2024 | Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma | Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied. 96% of patients received an infusion of f... |
| 05.11.2024 | Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 | New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell therapy manufacturing platform delivers fres... |
| 30.10.2024 | Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update | We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy.We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline w... |
| 07.10.2024 | Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth | Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effectiv... |
| 16.09.2024 | Galapagos receives transparency notification from EcoR1 Capital | Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC.
Pursuant to Belgian transparency legislation1, Galapagos receiv... |
| 03.09.2024 | Galapagos ontvangt transparantieverklaring van FMR LLC | Mechelen, België; 3 september 2024, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft een kennisgeving van belangrijke deelneming ontvangen van FMR LLC.
Overeenkomstig de Belgische transparantiewetgev... |
| 03.09.2024 | Galapagos receives transparency notification from FMR LLC | Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.
Pursuant to Belgian transparency legislation1, Galapagos received a transp... |
| 03.09.2024 | Galapagos receives transparency notification from FMR LLC | Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.
Pursuant to Belgian transparency legislation1, Galapagos received a transp... |
| 23.08.2024 | Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma | Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos’ Investigational N... |
| 23.08.2024 | Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma | Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos’ Investigational N... |
| 23.08.2024 | Galapagos kondigt FDA-goedkeuring aan van IND-aanvraag voor fase 1/2 ATALANTA-1 studie van CD19 CAR-T, GLPG5101, in recidief/refractair non-Hodgkin lymfoom | Mechelen, België; 23 augustus 2024, 07:00 CET; gereglementeerde informatie - voorwetenschap - Galapagos NV (Euronext & NASDAQ: GLPG) heeft vandaag aangekondigd dat de U.S. Food and Drug Administration (FDA) Galapagos' Investigational Ne... |
| 20.08.2024 | Galapagos ontvangt transparantieverklaring van FMR LLC | Mechelen, België; 20 augustus 2024, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft een kennisgeving van belangrijke deelneming ontvangen van FMR LLC.
Overeenkomstig de Belgische transparantiewetgev... |
| 20.08.2024 | Galapagos receives transparency notification from FMR LLC | Mechelen, Belgium; 20 August 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.
Pursuant to Belgian transparency legislation1, Galapagos received a transpar... |
| 20.08.2024 | Galapagos receives transparency notification from FMR LLC | Mechelen, Belgium; 20 August 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.
Pursuant to Belgian transparency legislation1, Galapagos received a transpar... |
| 01.08.2024 | Galapagos reports half-year 2024 financial results and provides second quarter business update | Executing on our Forward, Faster strategy with strong progress in a pivotal year, focused on delivering regulatory and clinical milestones, expanding our cell therapy manufacturing capabilities, and advancing our early-stage programs.Submit... |
| 14.06.2024 | Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024 | Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/ref... |
| 14.06.2024 | Galapagos presenteert bemoedigende nieuwe resultaten voor CD19 CAR-T kandidaat GLPG5101 in non-Hodgkin lymfoom op EHA 2024 | Mechelen, België; 14 juni 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag aan dat het bemoedigende nieuwe resultaten zal presenteren van de lopende fase 1/2 ATALANTA-1 studie van CD19 CAR-T kandidaat, GLPG5101, ... |
| 14.06.2024 | Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024 | Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/ref... |
| 16.05.2024 | Galapagos creëert nieuwe inschrijvingsrechtenplannen | Mechelen, België; 16 mei 2024; 22:01 CET ; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt vandaag aan dat haar Raad van Bestuur 1.614.000 inschrijvingsrechten heeft gecreëerd onder nieuwe inschrijvingsrecht... |
| 16.05.2024 | Galapagos creates new subscription right plans | Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benef... |
| 15.05.2024 | Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S. | BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centers Collaboration enables rapid deployment of Galapagos' decentralized CAR-T pl... |
| 15.05.2024 | Galapagos en Blood Centers of America kondigen een strategische samenwerking aan om Galapagos' gedecentraliseerde CAR-T productienetwerk in de VS versneld op te schalen | BCA's nationale netwerk van bloedcentra zal gedecentraliseerde productiediensten leveren voor Galapagos’ CAR-T productkandidaten, dichtbij centra voor kankerbehandelingen De samenwerking maakt snelle inzet van Galapagos' gedecentraliseerde ... |
| 04.04.2024 | Galapagos toont innovatieve aanpak in hematologische kankerzorg met presentaties over klinische en translationele data op EBMT congres 2024 | Twee presentaties en een postersessie met eerder gepresenteerde preliminaire data van fase 1/2 CD19 CAR-T-studies in non-Hodgkin lymfoom (NHL) en chronische lymfatische leukemie (CLL) / Richter transformatie (RT).
Mechelen, België; 4 april ... |
| 04.04.2024 | Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 | Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT)
Mechelen, Belgium; 4 April 2024, 22:01 CET... |
| 22.02.2024 | Galapagos kondigt 2023 jaarresultaten en vooruitzichten 2024 aan | Financiële kerngetallen voor het hele jaar 2023: Netto groepsomzet van €783,5 miljoen in 2023, inclusief €112,3 miljoen nettoverkopen voor Jyseleca® Geldmiddelen en kortlopende financiële investeringen van €3,7 miljard per 31 december 2023 ... |
| 22.02.2024 | Galapagos announces full year 2023 results and outlook for 2024 | Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023 Operational cash burni of €414.8 million, within... |
| 15.02.2024 | Galapagos presenteert op de jaarlijkse EBMT-EHA meeting van 2024 | Toont betekenisvolle vooruitgang in gedecentraliseerde CAR T-cel productie en presenteert translationele en klinische gegevens van lopende fase 1/2 CD19 CAR-T studies
Mechelen, België; 15 februari 2024, 22:01 CET; Galapagos NV (Euronext &am... |
| 15.02.2024 | Galapagos presents at EBMT-EHA annual meeting 2024 | Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies
Mechelen, Belgium; 15 February 2024, 22:01 CET; Galapagos NV (Euronext & NASD... |
| 31.01.2024 | Galapagos completes transaction to transfer Jyseleca® business to Alfasigma | Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A.
As previously announc... |
| 31.01.2024 | Galapagos rondt transactie af om Jyseleca® business over te dragen aan Alfasigma | Mechelen, België; 31 januari 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) heeft vandaag aangekondigd dat de transactie om haar Jyseleca® (filgotinib) activiteiten over te dragen aan Alfasigma S.p.A. succesvol is afgerond.
Zoa... |
| 07.12.2023 | Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023 | Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, De... |
| 07.12.2023 | Galapagos organiseert een KOL-evenement op 10 december 2023 om 11:00 AM PST om nieuwe gegevens te bespreken die zijn gepresenteerd op ASH 2023 | Mechelen, België; 6 december 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag aan dat het een Key Opinion Leader (KOL) evenement zal organiseren tijdens de 65e ASH Annual Meeting & Exposition in San Diego, CA... |
| 15.06.2023 | Galapagos benoemt Thad Huston tot Chief Financial Officer en Chief Operating Officer | /EIN News/ -- Mechelen, België; 15 juni 2023, 22:01 CET; gereglementeerde informatie - Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag de benoeming aan van Thad Huston als Chief Financial Officer (CFO) en Chief Operating Officer... |
| 15.06.2023 | Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer | /EIN News/ -- Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) a... |
| 05.06.2023 | Galapagos toont CAR-T point-of-care productie en eerste fase 1/2 CLL-data met CD19 CAR-T kandidaat, GLPG5201, op het EHA 2023 congres | Alle 7 van de 7 in aanmerking komende patiënten met recidief/refractaire chronische lymfatische leukemie (rrCLL), met of zonder Richter-transformatie (RT), reageerden op de behandeling (Objective Response Rate van 100%)1 Bij GLPG5201 werd g... |
| 05.06.2023 | Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress | All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter’s Transformation (RT), responded to treatment (Objective Response Rate of 100%)1 GLPG5201 showed no cytokine release syn... |
| 05.05.2023 | Galapagos creates new subscription right plans | /EIN News/ -- Mechelen, Belgium; 5 May 2023, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,975,000 subscription rights under new subscription right plans ... |
| 05.05.2023 | Galapagos creëert nieuwe inschrijvingsrechtenplannen | /EIN News/ -- Mechelen, België; 5 mei 2023, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt vandaag aan dat haar Raad van Bestuur 1.975.000 inschrijvingsrechten heeft gecreëerd onder nieuwe inschr... |
| 04.05.2023 | Galapagos announces first quarter 2023 financial results | Progress with immunology and oncology pipeline: First patients dosed in pivotal Phase 3 OLINGUITO study with filgotinib in axial spondyloarthritis (AxSpA) Clinical sites opened to start patient recruitment in Phase 2 GALARISSO study with TY... |
| 04.05.2023 | Galapagos rapporteert financiële resultaten voor het eerste kwartaal van 2023 | Voortgang met immunologie en oncologie pijplijn: Eerste patiënten gedoseerd in pivotale fase 3 OLINGUITO-studie met filgotinib in axiale spondyloartritis (AxSpA) Klinische sites geopend voor de start van de rekrutering van patiënten in fase... |
| 27.02.2023 | Galapagos presenteert nieuwe data van langetermijn-uitbreidingsstudie van filgotinib bij colitis ulcerosa op jaarlijks ECCO congres 2023 | Zes presentaties tonen Galapagos' betrokkenheid bij inflammatoire darmziekten (IBD)
Nieuwe analyses van de fase 3 SELECTION en SELECTION langetermijn-uitbreidingsstudies (LTE) van Jyseleca® (filgotinib, een orale, eenmaal daagse, preferenti... |
| 27.02.2023 | Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023 | Six presentations demonstrate Galapagos’ commitment to the inflammatory bowel disease (IBD) community
New analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib, an oral, once daily, JAK1 pr... |
| 14.12.2021 | Ryvu announces option to license inflammation program exercised by Galapagos NV | KRAKOW, Poland, Dec. 14, 2021 /PRNewswire/ -- Ryvu Therapeutics S.A. (WSE: RVU) announced today that the pre-agreed criteria in the Option, License and Research Collaboration Agreement, announced between Ryvu and Galapagos on April 16, 2020... |
| 21.09.2021 | Galapagos : N.V., - Galapagos increases share capital through subscription right exercises | Galapagos increases share capital through subscription right exercises
Mechelen, Belgium; 20 September 2021, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subsc... |
| 17.09.2021 | Galapagos : N.V., - GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Mechelen, Belgium; 17 September 2021; 13.15 CET; Galapagos NV (Euronext & Nasdaq: GLP... |
| 15.07.2021 | Galapagos : N.V., - Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation | Galapagos demonstrates early clinical activity with
SIK2/3 inhibition in inflammation
Biologic effect of salt inducible kinase (SIK) mechanism in first patient studies supports further progression of Toledo portfolio
SIK2/3 inhibitor GLPG39... |
| 15.07.2021 | Galapagos : N.V., - Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study | Galapagos reports positive topline results with selective TYK2 inhibitor
GLPG3667 in Phase 1b psoriasis study
Generally safe and well tolerated
Positive efficacy signal in psoriasis patients at Week 4
40% of patients showed improvement of a... |
| 25.03.2021 | Galapagos : Statutory auditor's report on the non-consolidated financial statements per 31 December 2020 | Galapagos NV
Document subtitle= Verdana Heading 12 0/0 single
Galapagos NV
Statutory auditor's report to the shareholders' meeting for the year ended 31 December 2020 - Annual accounts
The original text of this report is in Dutch
/ Reviseur... |
| 07.08.2020 | GALAPAGOS NV
Galapagos : H1 Report 2020 | H1 Report
2020
CONTENTS
Contents The Galapagos group Letter from the management ........................... 4
COVID-19 impact ................................................ 8
At a glance ...................................................... |
| 02.07.2019 | Gilead to seek FDA approval for rheumatoid arthritis drug this year | Shares of Gilead were up 1.4 percent on the Nasdaq Tuesday morning following the news. Shares of Galapagos were up more than 4 percent on the Euronext Amsterdam and the Nasdaq.
The Phase III studies, FINCH 1 and FINCH 3, have both achieved ... |
| 31.03.2019 | Gilead, Galapagos’s filgotinib scores in Phase III rheumatoid arthritis trial, but questions remain | Gilead’s shares rose 3 percent Friday morning following the news, while Galapagos’s shares were up 25 percent by the early afternoon.
Filgotinib is a JAK inhibitor and in almost neck-and-neck competition against AbbVie’s upadacitinib, which... |
| 13.09.2018 | Galapagos raises $300M on the back of first PhIII filgotinib success; Incyte pushes into PhIII with topical Jakafi | → Galapagos $GLPG wasn’t about to let the success of its first Phase III for filgotinib — handled by lead partner Gilead — go by without a quick raise. The biotech garnered $300 million from the sale of its stock.
→ Incyte $INCY... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 13.05.2015 | Eurozone GDP, and Dupont shareholders vote — 5 things to know today | Hello friends and Fortune readers.
Wall Street stock futures are higher this morning, helped by hopes for more stimulus measures in China and a broadly positive set of 1Q GDP data from Europe.
Paid Content What you need to know about growin... |
| 22.02.2012 | GSK grips arthritis compounds from drug partner Galapagos | The Galapagos/GSK strategic alliance dates to 2006, when the companies partnered to discover and develop drugs that target osteoarthritis. In 2007 and 2008, the alliance was expanded to include other targets, such as antibacterials and anti... |
| 21.09.2005 | Galapagos and BioFocus form a new force in drug discovery | Galapagos and BioFocus form a new force in drug discovery
21-09-2005
The boards of Galapagos NV, a genomics-based biotechnology company (Euronext Brussels: GLPG; Euronext Amsterdam: GLPGA) and BioFocus plc, an integrated drug discovery comp... |
| - | Gilead, Galapagos’s filgotinib scores in Phase III rheumatoid arthritis trial, but questions remain | Biotech giant Gilead Sciences and a European partner scored a win Thursday with a positive Phase III study of a new drug in rheumatoid arthritis, but analysts say they still have challenges they’ll have to overcome.
Foster City, California-... |
| - | Gilead to seek FDA approval for rheumatoid arthritis drug this year | A U.S. biotech company plans to seek Food and Drug Administration approval for a drug to treat autoimmune diseases this year.
Foster City, California-based Gilead Sciences said Monday that it would file an approval application for filgotini... |
| - | GSK grips arthritis compounds from drug partner Galapagos | GlaxoSmithKline (NYSE:GSK) is strengthening its prospects of developing a new arthritis treatment by licensing two anti-inflammatory compounds from drug partner Galapagos NV (OTC:GLPYY).
Belgium-based Galapagos said GSK has exercised its op... |
| - | Cambridge-based Qureight raises £1.5 million to curate collection of complex disease data | Cambridge-based data company Qureight has raised £1.5 million seed funding to deliver the next generation of its ground-breaking platform and capitalise on its vision to house the world’s largest collection of data from complex diseases. Th... |
